{"product_id":"viral-hepatitis-isbn-9780470672952","title":"Viral Hepatitis","description":"\u003cp\u003eThe 4th edition of \u003ci\u003eViral Hepatitis\u003c\/i\u003e covers comprehensively the entire complex field of infections caused by all of the different hepatitis viruses, which affect many millions of people throughout the world with considerable morbidity and mortality.\u003c\/p\u003e \u003cp\u003eHoward Thomas and Arie Zuckerman are joined by Anna Lok from the USA and Stephen Locarnini from Australia as Editors.  They have recruited leading researchers and physicians from many countries, who have produced an authoritative account of current knowledge and research on this important infection, including new insights into immune response to HBV and HCV.\u003c\/p\u003e \u003cp\u003eThe result is a comprehensive account on all aspects of viral hepatitis, including rapid advances in the diagnosis, management, treatment and prevention of a complex infection, which in the case of hepatitis B, C and D may lead to severe complications including chronic hepatitis, cirrhosis and hepatocellular carcinoma.\u003c\/p\u003e \u003cp\u003eThe latest edition of \u003ci\u003eViral Hepatitis\u003c\/i\u003e offers an essential resource of current information for hepatologists, gastroenterologists, infectious diseases specialists and other clinicians, researchers, public health physicians and National and International Health Authorities.\u003c\/p\u003e \u003cp\u003eList of Contributors vii\u003c\/p\u003e \u003cp\u003ePreface xii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection I: Introduction to Liver Biology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Liver regeneration and fibrosis 3\u003cbr\u003e \u003ci\u003eStuart J. Forbes and Malcolm R. Alison\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Hepatic immunology 13\u003cbr\u003e \u003ci\u003eGyongyi Szabo and Johanna Bruneau\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection II: Hepatitis A Virus\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3 Structure, molecular virology, natural history, and experimental models 29\u003cbr\u003e \u003ci\u003eGerardo G. Kaplan, Krishnamurthy Konduru, Mohanraj Manangeeswaran, Jerome Jacques, Nadia Amharref, and Siham Nakamura\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Epidemiology and prevention 43\u003cbr\u003e \u003ci\u003eBenjamin Cowie and Stephen A. Locarnini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection III: Hepatitis B Virus and Other\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eHepadnaviridae\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Structure and molecular virology 65\u003cbr\u003e \u003ci\u003eSouphalone Luangsay and Fabien Zoulim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Epidemiology and prevention 81\u003cbr\u003e \u003ci\u003ePhilip R. Spradling, Dale J. Hu, and Brian J. McMahon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Other Hepadnaviridae (Avihepadnaviridae (DHBV) and Orthohepadnaviridae (WHV)) 96\u003cbr\u003e \u003ci\u003eStephen A. Locarnini and Michael Roggendorf\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Molecular variants of hepatitis B surface antigen (HBsAg) 107\u003cbr\u003e \u003ci\u003eSeyed Mohammad Jazayeri, Seyed Moayed Alavian, Payam Dindoost, Howard C. Thomas, and Peter Karayiannis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Molecular variants of the precore, core, and core promoter regions of hepatitis B virus, and theirclinical significance 127\u003cbr\u003e \u003ci\u003ePeter Karayiannis, William F. Carman, and Howard C. Thomas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Natural history of chronic hepatitis B virus infection 143\u003cbr\u003e \u003ci\u003eYun-Fan Liaw\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Extrahepatic manifestations of hepatitis B infection 154\u003cbr\u003e \u003ci\u003eChristian Trépo, Majid Amiri, and Loïc Guillevin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Hepatitis B and hepatocellular carcinoma 163\u003cbr\u003e \u003ci\u003eMarie Annick Buendia and Pierre Tiollais\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Murine models and human studies of pathogenesis of chronic hepatitis B 176\u003cbr\u003e \u003ci\u003eJuandy Jo, Anthony Tanoto Tan, and Antonio Bertoletti\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Treatment of hepatitis B 188\u003cbr\u003e \u003ci\u003eHellan K. Kwon and Anna S.F. Lok\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Liver transplantation for chronic hepatitis B and C 203\u003cbr\u003e \u003ci\u003eEd Gane\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection IV: Hepatitis C Virus\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e16 Structure and molecular virology 221\u003cbr\u003e \u003ci\u003eMichael J. McGarvey and Michael Houghton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Epidemiology and prevention 246\u003cbr\u003e \u003ci\u003eJosep Quer and Juan I. Esteban Mur\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 The immune response to HCV in acute and chronic infection 266\u003cbr\u003e \u003ci\u003eRobert Thimme and Salim I. Khakoo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Animal models of hepatitis C virus infection 280\u003cbr\u003e \u003ci\u003ePatrizia Farci and Jens Bukh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Extrahepatic manifestations of hepatitis C virus infection 295\u003cbr\u003e \u003ci\u003eBenjamin Maasoumy, Michael P. Manns, and Markus Cornberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Central nervous system complications of hepatitis c virus infection 310\u003cbr\u003e \u003ci\u003eDaniel M. Forton, Simon Taylor-Robinson, Markus Gess, and Howard C. Thomas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 In vitro replication models 325\u003cbr\u003e \u003ci\u003eVolker Lohmann, Sandra Bühler, and Ralf Bartenschlager\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Natural history of chronic HCV infection and non-invasive assessment of hepatic fibrosis 341\u003cbr\u003e \u003ci\u003eLaurent Castera\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Hepatitis C and hepatocellular carcinoma 353\u003cbr\u003e \u003ci\u003eHubert E. Blum\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Treatment of hepatitis C 362\u003cbr\u003e \u003ci\u003eChristoph Welsch and Stefan Zeuzem\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Development of anti-HCV drugs 377\u003cbr\u003e \u003ci\u003eEsperance Schaefer and Raymond T. Chung\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection V: Hepatitis D Virus\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e27 Structure and molecular virology 395\u003cbr\u003e \u003ci\u003eFrancesco Negro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Epidemiology and natural history 403\u003cbr\u003e \u003ci\u003eHeiner Wedemeyer, Svenja Hardtke, and Michael P. Manns\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Treatment of hepatitis D 410\u003cbr\u003e \u003ci\u003eAlessia Ciancio and Mario Rizzetto\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VI: Hepatitis E Virus\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e30 Structure and molecular virology 419\u003cbr\u003e \u003ci\u003eXiang-Jin Meng\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Epidemiology, experimental models, and prevention: zoonotic aspects of hepatitis E 431\u003cbr\u003e \u003ci\u003eSubrat Kumar Panda and Satya Pavan Kumar Varma\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Clinical and pathological features, and diagnosis 442\u003cbr\u003e \u003ci\u003eCyril Sieberhagen and Matthew E. Cramp\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VII: Clinical Aspects of Viral Liver Disease\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e33 Clinical and diagnostic aspects of viral hepatitis 453\u003cbr\u003e \u003ci\u003eCui Li Lin, Chelsea Q. Xu, and Jack R. Wands\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Treatment of acute hepatitis, severe acute hepatitis, and acute liver failure 468\u003cbr\u003e \u003ci\u003eHans L. Tillmann and Alastair D. Smith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Hepatitis and hemophilia 486\u003cbr\u003e \u003ci\u003eMike Makris and Geoffrey Dusheiko\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Hepatitis in persons infected with HIV 494\u003cbr\u003e \u003ci\u003eJanice Main and Brendan McCarron\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Migration, hepatitis B, and hepatitis C 506\u003cbr\u003e \u003ci\u003eManuel Carballo, Rowan Cody, Megan Kelly and Angelos Hatzakis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 Occupational aspects of hepatitis 515\u003cbr\u003e \u003ci\u003eWilliam L. Irving and Fortune Ncube\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e39 Neonatal and pediatric infection 529\u003cbr\u003e \u003ci\u003eDeirdre A. Kelly and C.Y. William Tong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e40 Management of hepatocellular carcinoma 544\u003cbr\u003e \u003ci\u003eMassimo Iavarone and Massimo Colombo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 Application of molecular biology to the diagnosis of viral hepatitis 552\u003cbr\u003e \u003ci\u003eStéphane Chevaliez, Christophe Rodriguez, and Jean-Michel Pawlotsky\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Disinfection and sterilization 564\u003cbr\u003e \u003ci\u003eMartin S. Favero and Walter W. Bond\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e43 Evolution of hepatitis viruses 575\u003cbr\u003e \u003ci\u003ePeter Simmonds and Donald B. Smith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 587\u003c\/p\u003e \u003cp\u003e\u003cb\u003eArie Zuckerman\u003c\/b\u003e is chair of the Hepatitis B Foundation UK. He was the Director of WHO Collaborating Centre for Reference and Research on Viral Hepatitis from 1974-1989 and 1990-2006. He was also?Principal and Dean of the Royal Free and University College Medical School and Principal and Dean of the Royal Free Hospital School of Medicine.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHoward Thomas\u003c\/b\u003e?is Vice President of British Liver Trust, 1993-present and Hepatitis B Foundation — Trustee, 2005-present. He was also President of British Association for the Study of the Liver 1996-1998.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAnna Lok\u003c\/b\u003e is a Professor of Internal Medicine and Director of Clinical Hepatology at the University of Michigan Medical Center. Her contributions include: hepatitis B's role in infection, treatment of hepatitis-induced diseases, development of cost-effective methods for preventing recurrent hep B infection following liver transplantation, and long-term effects of interferon treatment in patients with hep C.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eStephen Locarnini\u003c\/b\u003e's research group is composed of: molecular diagnostics, new drug targets in HBV and molecular pathogenesis. Stephen is also the Director of the World Health Organisation (WHO) Collaborating Centre for Virus Reference and Research at the VIDRL.\u003c\/p\u003e  \u003cp\u003eVIRAL HEPATITIS, 4\u003csup\u003eTH\u003c\/sup\u003e EDITION\u003c\/p\u003e \u003cp\u003eEdited by Howard C. Thomas, Imperial College London, London, UK\u003cbr\u003e Arie J. Zuckerman, University College London, London, UK\u003cbr\u003e Anna S. F. Lok, University of Michigan Health System, Ann Arbor, MI, USA\u003cbr\u003e Stephen A. Locarnini, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia\u003c\/p\u003e \u003cp\u003eThe 4\u003csup\u003eth\u003c\/sup\u003e edition of \u003ci\u003eViral Hepatitis\u003c\/i\u003e covers comprehensively the entire complex field of infections caused by all of the different hepatitis viruses, which affect many millions of people throughout the world with considerable morbidity and mortality.\u003c\/p\u003e \u003cp\u003eHoward Thomas and Arie Zuckerman are joined by Anna Lok from the USA and Stephen Locarnini from Australia as Editors.  They have recruited leading researchers and physicians from many countries, who have produced an authoritative account of current knowledge and research on this important infection, including new insights into immune response to HBV and HCV. \u003c\/p\u003e \u003cp\u003eThe result is a comprehensive account on all aspects of viral hepatitis, including rapid advances in the diagnosis, management, treatment and prevention of a complex infection, which in the case of hepatitis B, C and D may lead to severe complications including chronic hepatitis, cirrhosis and hepatocellular carcinoma.\u003c\/p\u003e \u003cp\u003eThe latest edition of \u003ci\u003eViral Hepatitis\u003c\/i\u003e offers an essential resource of current information for hepatologists, gastroenterologists, infectious diseases specialists and other clinicians, researchers, public health physicians and National and International Health Authorities.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47990454288613,"sku":"NP9780470672952","price":314.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470672952.jpg?v=1761787896","url":"https:\/\/k12savings.com\/products\/viral-hepatitis-isbn-9780470672952","provider":"K12savings","version":"1.0","type":"link"}